These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29572277)

  • 21. Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.
    Schneider LS; Kennedy RE; Cutter GR;
    Alzheimers Dement; 2010 Sep; 6(5):367-77. PubMed ID: 20813339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serial MRI and CSF biomarkers in normal aging, MCI, and AD.
    Vemuri P; Wiste HJ; Weigand SD; Knopman DS; Trojanowski JQ; Shaw LM; Bernstein MA; Aisen PS; Weiner M; Petersen RC; Jack CR;
    Neurology; 2010 Jul; 75(2):143-51. PubMed ID: 20625167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease.
    Geijselaers SLC; Aalten P; Ramakers IHGB; De Deyn PP; Heijboer AC; Koek HL; OldeRikkert MGM; Papma JM; Reesink FE; Smits LL; Stehouwer CDA; Teunissen CE; Verhey FRJ; van der Flier WM; Biessels GJ;
    J Alzheimers Dis; 2018; 61(1):309-320. PubMed ID: 29154275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease.
    Brys M; Glodzik L; Mosconi L; Switalski R; De Santi S; Pirraglia E; Rich K; Kim BC; Mehta P; Zinkowski R; Pratico D; Wallin A; Zetterberg H; Tsui WH; Rusinek H; Blennow K; de Leon MJ
    J Alzheimers Dis; 2009; 16(2):351-62. PubMed ID: 19221425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations.
    Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR;
    Neurology; 2009 Jul; 73(4):287-93. PubMed ID: 19636048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.
    van Maurik IS; Zwan MD; Tijms BM; Bouwman FH; Teunissen CE; Scheltens P; Wattjes MP; Barkhof F; Berkhof J; van der Flier WM;
    JAMA Neurol; 2017 Dec; 74(12):1481-1491. PubMed ID: 29049480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau.
    Lafirdeen ASM; Cognat E; Sabia S; Hourregue C; Lilamand M; Dugravot A; Bouaziz-Amar E; Laplanche JL; Hugon J; Singh-Manoux A; Paquet C; Dumurgier J
    PLoS One; 2019; 14(5):e0217026. PubMed ID: 31086391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease.
    Liguori C; Stefani A; Sancesario G; Sancesario GM; Marciani MG; Pierantozzi M
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):655-9. PubMed ID: 25121572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease.
    Fjell AM; Walhovd KB; Fennema-Notestine C; McEvoy LK; Hagler DJ; Holland D; Brewer JB; Dale AM;
    J Neurosci; 2010 Feb; 30(6):2088-101. PubMed ID: 20147537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
    de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
    Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease.
    Ott BR; Cohen RA; Gongvatana A; Okonkwo OC; Johanson CE; Stopa EG; Donahue JE; Silverberg GD;
    J Alzheimers Dis; 2010; 20(2):647-57. PubMed ID: 20182051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. White matter signal abnormality quality differentiates mild cognitive impairment that converts to Alzheimer's disease from nonconverters.
    Lindemer ER; Salat DH; Smith EE; Nguyen K; Fischl B; Greve DN;
    Neurobiol Aging; 2015 Sep; 36(9):2447-57. PubMed ID: 26095760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.